Merus Announces Business Update Conference Call
ET
- ET
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m. - Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
- Merus plans to report initial interim safety and efficacy data from this cohort in the first half of 2024.
- Merus will hold a conference call and webcast for investors on October 16, 2023 at 7:30 a.m.